ENSYSCE BIOSCIENCES, INC. Retained Earnings
ENSYSCE BIOSCIENCES, INC. (ENSC) had Retained Earnings of -$145.85 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$145.85M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$143.28M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$139.72M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$136.95M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$145.85M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$143.28M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | -$139.72M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$136.95M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | -$133.22M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$131.49M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$129.54M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$125.98M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$126.64M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$124.67M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$121.56M 10-K · filed 2025-03-10 | |
| 2023-09-30 | -$118.05M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | -$115.36M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | -$113.13M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$110.93M 10-K · filed 2024-03-15 | |
| 2022-09-30 | -$105.41M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$95.51M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$87.51M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$85.85M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$75.01M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$57.84M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | -$2.92M 10-Q · filed 2021-06-08 | |
| 2020-12-31 | -$55.96M 10-K · filed 2022-03-31 | $5.00M 10-K · filed 2021-03-15 |
| 2020-09-30 | $1.51M 10-K/A · filed 2021-06-08 | $4.94M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$2.70M 10-K/A · filed 2021-06-08 | $4.72M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $1.66M 10-K/A · filed 2021-06-08 | $2.11M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$136.71K 10-K/A · filed 2021-06-08 | $2.46M 10-K · filed 2020-03-10 |
| 2019-09-30 | $2.82M 10-K/A · filed 2021-06-08 | $3.78M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $2.47M 10-K/A · filed 2021-06-08 | $3.29M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $2.05M 10-K/A · filed 2021-06-08 | $2.87M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $930.59K 10-K/A · filed 2021-06-08 | $2.09M 10-K · filed 2019-03-11 |
| 2018-09-30 | -$1.36M 10-K/A · filed 2021-06-08 | $1.37M 10-Q · filed 2018-11-07 |
| 2018-06-30 | -$233.77K 10-K/A · filed 2021-06-08 | $789.98K 10-Q · filed 2018-08-01 |
| 2018-03-31 | -$375.88K 10-K/A · filed 2021-06-08 | $374.87K 10-Q · filed 2018-05-03 |
| 2017-12-31 | -$1.12M 10-K/A · filed 2021-06-08 | -$31.19K 10-K · filed 2018-03-09 |
| 2017-12-05 | -$5.16K 10-K/A · filed 2021-06-08 | |
| 2017-09-30 | -$5.00K 10-Q · filed 2018-01-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |